Beryl Drugs Ltd - Stock Valuation and Financial Performance

BSE: 524606 | NSE: | Pharmaceuticals & Drugs | Small Cap

Beryl Drugs Share Price

28.14 1.83 6.96%
as on 21-Feb'25 16:59

DeciZen - make an informed investing decision on Beryl Drugs

M-Cap below 100cr DeciZen not available

Beryl Drugs stock performance -

P/E Ratio (SA):
182.97
Market Cap:
14.3 Cr.
52-wk low:
24.2
52-wk high:
46

Is Beryl Drugs Ltd an attractive stock to invest in?

1. Is Beryl Drugs Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Beryl Drugs Ltd is a below average quality company.

2. Is Beryl Drugs Ltd undervalued or overvalued?

The key valuation ratios of Beryl Drugs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Beryl Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Beryl Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Beryl Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Beryl Drugs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 4.9%5.6%4.5%16.9%10%4.1%6.3%-3.8%11.5%11.1%-
Value Creation
Index
-0.7-0.6-0.70.2-0.3-0.7-0.6-1.3-0.2-0.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 13.313.11115.11312.814.114.626.926.720
Sales YoY Gr.--1.4%-16.2%37.8%-14.4%-1.1%9.9%3.6%84%-0.5%-
Adj EPS 0.20.20.21.31.20.1-0.2-1.31.51.50.2
YoY Gr.-20%16.7%528.6%-10.6%-92.4%-266.7%NANA-0.7%-
BVPS (₹) 12.813.113.413.114.81515.614.315.917.618.4
Adj Net
Profit
0.10.10.10.70.60.1-0.1-0.70.80.80
Cash Flow from Ops. 0.7-0.10.3-0.13.40.20.3-0.52.40.8-
Debt/CF from Ops. 2.5-13.56.3-14.8128.315.1-11.31.96.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.1%15.6%23.8%-0.5%
Adj EPS 29.2%4.9%NA-0.7%
BVPS3.6%3.5%4%10.7%
Share Price -3% 44.9% 38.6% -35.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
1.21.41.6108.40.6-1-8.61090.8
Op. Profit
Mgn %
5.33.84.56.987.110.337.48.210.8
Net Profit
Mgn %
0.60.714.44.60.4-0.5-4.52.92.90.4
Debt to
Equity
0.30.30.30.20.40.70.70.70.60.6-
Working Cap
Days
16517021518519518623226614615177
Cash Conv.
Cycle
80104149114957293114587634

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 23.79%

Debt to equity has declined versus last 3 years average to 0.57

Return on Equity has declined versus last 3 years average to 0.80%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at -33.65%

Latest Financials - Beryl Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) 0.2 -
TTM Sales (₹ Cr.) 20.2 -
BVPS (₹.) 18.4 -
Reserves (₹ Cr.) 4 -
P/BV 1.53 -
PE 182.97 -
From the Market
52 Week Low / High (₹) 24.20 / 46.00
All Time Low / High (₹) 0.60 / 53.00
Market Cap (₹ Cr.) 14.3
Equity (₹ Cr.) 5.1
Face Value (₹) 10
Industry PE 37.5

Quarterly Results

 Mar'24 YoY Gr. Rt. %Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %
Sales (₹ Cr.) 369 7.6366 4382 10.3388 10.8
Adj EPS (₹) 2.1 505.71.6 54.52.4 104.22.4 106.8
Op. Profit Mgn % 3.73 63 bps3.75 -9 bps4.99 325 bps4.93 312 bps
Net Profit Mgn % 3.85 331 bps2.86 133 bps4.25 196 bps4.17 195 bps

Management X-Ray of Beryl Drugs:

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:26.38%Institutions:0%Non-Institutions:73.62%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep22Dec22Mar23Jun23Sep23Dec23Mar24Jun24Sep24Dec240%5%10%15%20%25%30%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Beryl Drugs

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of Beryl Drugs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Alembic Pharma 802.8 -10.6 (-1.3%) Small Cap 6,229 30.8 9.6 26.4 3.2
Laurus Labs 521.1 -15.4 (-2.9%) Small Cap 5,041 3.7 3.1 144.5 6.9
Piramal Pharma 208.6 -9.5 (-4.3%) Small Cap 4,390 5.2 8.4 42.1 4.1
Ajanta Pharma 2,607.3 -63.1 (-2.4%) Small Cap 4,209 71.9 19 37.2 8.5
Gland Pharma 1,524.3 3.9 (0.3%) Small Cap 4,167 68.1 24.8 22.3 2.7
Natco Pharma 797.8 4.8 (0.6%) Small Cap 3,999 104.1 34.5 7.6 2
Granules India 509 -18.4 (-3.5%) Small Cap 3,755 13.3 11.7 39.7 3.9
Emcure Pharma 996.8 5.2 (0.5%) Small Cap 3,498 8.5 4.4 116.8 6.5
JB Chem & Pharma 1,605.5 -25 (-1.5%) Small Cap 3,299 40.4 16.1 40.4 7.7
Sanofi India 5,076.8 -91.3 (-1.8%) Small Cap 2,851 184.4 20.8 28 15.5
Shows rows:

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales13.2913.1110.9915.1412.9612.8214.0914.6026.8726.73
Operating Expenses 12.5812.6110.5014.1011.9411.9112.6414.1724.8824.53
Manufacturing Costs8.448.917.079.447.497.828.779.8817.0616.56
Material Costs1.791.511.151.691.440.870.730.601.571.31
Employee Cost 1.141.130.900.770.850.851.031.131.491.72
Other Costs 1.211.061.382.202.162.372.122.564.774.94
Operating Profit 0.700.500.491.041.020.911.450.431.992.20
Operating Profit Margin (%) 5.3%3.8%4.5%6.9%7.9%7.1%10.3%3.0%7.4%8.2%
Other Income 0.210.370.260.690.240.230.190.160.280.48
Interest 0.260.210.210.130.150.320.470.460.470.47
Depreciation 0.520.410.380.330.320.661.271.090.811.20
Exceptional Items 0000000.45000
Profit Before Tax 0.140.250.171.270.800.160.35-0.950.981.01
Tax 0.050.080.050.280.210.110.11-0.290.220.24
Profit After Tax 0.080.170.120.990.590.050.24-0.660.770.77
PAT Margin (%) 0.6%1.3%1.1%6.6%4.6%0.4%1.7%-4.5%2.9%2.9%
Adjusted EPS (₹)0.20.30.22.01.20.10.5-1.31.51.5
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 6.506.666.796.677.537.637.937.298.078.92
Share Capital 5.095.095.095.095.095.095.095.095.095.09
Reserves 1.401.571.701.572.432.532.842.202.973.83
Minority Interest0000000000
Debt1.701.681.691.463.054.714.345.294.545.09
Long Term Debt0.0200.090.071.302.311.991.682.712.40
Short Term Debt1.681.671.601.391.762.392.353.621.842.69
Trade Payables1.630.741.161.451.791.802.223.063.252.02
Others Liabilities 0.880.821.431.222.122.784.1621.621.67
Total Liabilities 10.719.9111.0710.8014.4916.9118.6517.6517.4817.71

Fixed Assets

Gross Block8.538.969.152.672.549.8410.099.6910.4411.65
Accumulated Depreciation6.116.526.890.620.871.502.763.834.635.68
Net Fixed Assets2.432.442.262.041.678.347.335.865.815.96
CWIP 0.24000.086.2400000
Investments 0.680.680.680.390.770.820.120.160.150
Inventories1.501.542.691.350.761.162.272.981.051.26
Trade Receivables3.703.533.604.833.443.454.544.456.907.58
Cash Equivalents 0.820.630.770.140.100.400.450.670.570.22
Others Assets1.351.071.081.971.522.743.943.532.992.68
Total Assets 10.719.9111.0710.8014.4916.9118.6517.6517.4817.71

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 0.70-0.130.27-0.103.350.180.34-0.472.390.82
PBT 0.170.270.171.270.800.160.35-0.950.981.01
Adjustment 0.960.660.40-0.390.280.831.141.371.121.53
Changes in Working Capital 0.14-0.54-0.13-0.872.53-0.66-1.13-0.850.35-1.52
Tax Paid -0.21-0.16-0.12-0.11-0.26-0.15-0.02-0.03-0.06-0.20
Cash Flow From Investing Activity 0.020.170.05-0.03-5.01-1.550.260.52-1.18-1.08
Capex -0.23-0.20-0.200.17-0.06-1.88-0.240.40-0.75-1.33
Net Investments 0.06000.28000.97000.22
Others 0.200.370.25-0.48-4.950.32-0.480.13-0.430.03
Cash Flow From Financing Activity -0.09-0.23-0.19-0.361.621.67-0.54-0.24-1.200.10
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 000.09-0.021.391.35-0.07-0.311.03-0.25
Interest Paid -0.26-0.21-0.20-0.13-0.15-0.32-0.47-0.41-0.44-0.46
Dividend Paid 0000000000
Others 0.17-0.02-0.08-0.210.370.6400.48-1.800.81
Net Cash Flow 0.63-0.190.13-0.49-0.040.300.06-0.180.01-0.16
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)1.312.541.7414.88.350.633.09-8.68109.07
ROCE (%)4.925.554.4816.889.964.056.28-3.8211.5111.14
Asset Turnover Ratio1.341.321.091.41.020.820.790.81.531.52
PAT to CFO Conversion(x)8.75-0.762.25-0.15.683.61.42N/A3.11.06
Working Capital Days
Receivable Days8497114100116981041127799
Inventory Days39416748302744662716
Payable Days3032863022824107551,0061,617735734

Beryl Drugs Ltd Stock News

Beryl Drugs Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Beryl Drugs on 21-Feb-2025 16:59 is ₹28.14.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Feb-2025 16:59 the market cap of Beryl Drugs stood at ₹14.27.
The latest P/E ratio of Beryl Drugs as of 21-Feb-2025 16:59 is 183.0.
The latest P/B ratio of Beryl Drugs as of 21-Feb-2025 16:59 is 1.53.
The 52-week high of Beryl Drugs is ₹46.00 and the 52-week low is ₹24.20.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beryl Drugs is ₹20.15 ( Cr.) .

About Beryl Drugs Ltd

Beryl Drugs incorporated in 1993 is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.

Beryl has emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products. 

The manufacturing facilities of the company are in compliance with WHO GMP specifications.

Company owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.

The shares of Beryl Drugs are listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.

Products manufactured by the company:

  • Small volume injectables in liquid form
  • Small volume injectables in dry powder form
  • Variety of eye and ear drops
  • I.V.Fluids in polypack and glass bottles
  • Variety of vetrinary medicines

Award/recognition

The company has received ISO 9001:2000 certification for its quality management.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on